-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $24

Benzinga·05/14/2025 17:57:38
Listen to the news
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $28 to $24.